Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BDTX
BDTX logo

BDTX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Black Diamond Therapeutics Inc (BDTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.080
1 Day change
5.58%
52 Week Range
4.940
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BDTX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows some short-term technical strength and bullish options sentiment, but the lack of recent news, no strong proprietary buy signal, neutral insider/hedge fund activity, and weak near-term trend expectations make this more of a watchlist name than an immediate long-term purchase.

Technical Analysis

Price is sitting near 2.01, just below the 2.067 resistance level and above the 1.965 pivot, which suggests the stock is attempting to hold recent gains. MACD histogram is positive and expanding, indicating improving momentum. However, RSI_6 at 72.7 is elevated, so the move is already extended in the short term. Moving averages are converging, which usually signals an indecisive trend rather than a strong confirmed uptrend. The next meaningful resistance is 2.067, while support is 1.798. Overall, the technical picture is mildly bullish short term but not strong enough to justify an immediate long-term buy.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish based on the very low open interest put-call ratio of 0.14, which shows calls far outweigh puts. The volume put-call ratio of 0.0 also reflects call-only activity on the day. However, total option volume is very small at 28 contracts, so conviction is limited. Implied volatility is extremely high at 400.77%, with IV percentile at 100 and IV rank at 128.8, which signals very expensive options and heightened speculation rather than stable long-term sentiment.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
4

Positive Catalysts

  • ["H.C. Wainwright raised the price target to $11 from $10 and kept a Buy rating.", "Positive MACD momentum suggests short-term technical improvement.", "Options positioning is heavily call-skewed, indicating bullish trader sentiment.", "Price is holding above pivot support and trading near recent resistance, showing some accumulation interest."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst.", "AI Stock Picker shows no signal today.", "SwingMax shows no recent signal.", "Hedge fund activity is neutral over the last quarter.", "Insider activity is neutral over the last month.", "Near-term pattern expectations are weak, with projected declines over the next week and month.", "RSI is elevated, suggesting the stock may be stretched in the short term.", "Options volatility is extremely high, which usually reflects uncertainty rather than clean long-term visibility."]

Financial Performance

No usable latest-quarter financial snapshot was provided due to an error, so there is not enough financial data here to assess revenue or earnings growth trends. The latest quarter season is therefore not available from the data supplied.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is constructive but not broadly strong from the limited data. On 2026-04-29, H.C. Wainwright's Robert Burns raised the price target to $11 from $10 and maintained a Buy rating. That is a positive revision, but it appears to be a single analyst update rather than a broad upward revision trend. Overall, Wall Street pros are mildly bullish, but the lack of wider follow-through and the absence of fresh catalysts keep the view from being a strong conviction buy.

Wall Street analysts forecast BDTX stock price to rise
5 Analyst Rating
Wall Street analysts forecast BDTX stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.970
sliders
Low
8
Averages
9
High
10
Current: 1.970
sliders
Low
8
Averages
9
High
10
H.C. Wainwright
Robert Burns
Buy
maintain
$10 -> $11
AI Analysis
2026-04-29
Reason
H.C. Wainwright
Robert Burns
Price Target
$10 -> $11
AI Analysis
2026-04-29
maintain
Buy
Reason
H.C. Wainwright analyst Robert Burns raised the firm's price target on Black Diamond Therapeutics to $11 from $10 and keeps a Buy rating on the shares.
Wedbush
Outperform
maintain
$13 -> $14
2026-03-17
Reason
Wedbush
Price Target
$13 -> $14
2026-03-17
maintain
Outperform
Reason
Wedbush raised the firm's price target on Black Diamond Therapeutics to $14 from $13 and keeps an Outperform rating on the shares following quarterly results and updates regarding silevertinib clinical development. As a reminder, preliminary Phae 2 data for silever in NSCLC patients harboring uncommon EGFR mutations were reported in December. Wedbush looks forward to additional data readouts and expanding silevertinib development in the coming months.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BDTX
Unlock Now

People Also Watch